Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Proteins, Antibodies, ADCs Logo (drop shadow)

PART OF NEXTGEN BIOMED 2026

24 - 25 March 2026 | QEII Centre, London, UK

Programme Summary

Join world-class experts at our annual Proteins, Antibodies & ADCs programme – uncover breakthrough strategies, pioneering technologies, and transformative innovations shaping the next generation of biotherapeutics. From cutting-edge protein and antibody engineering to advanced bioanalytics, real-world case studies, and game-changing
upstream and downstream processing, this programme delivers the insights driving tomorrow’s therapies today.

Hear from past attendees of the NextGen Biomed 2025 conference

DAY TWO

Proteins, Antibodies, ADCs Keynote Address

CHARLOTTE DEANE MBE, Professor, University of Oxford

Professor Charlotte Deane MBE is a bioinformatician at the University of Oxford, known for pioneering work in protein and antibody modelling and for developing widely used research tools. She led UKRI’s COVID-19 response, earning an MBE in 2022, and has held senior roles including Head of Oxford’s Statistics Department. In 2023, she became Executive Chair of EPSRC, highlighting her impact on science, leadership, and policy.

2026 Highlights

Dive into breakthrough technologies shaping biologics discovery & development from protein and antibody display to AI-driven engineering, stability-focused analytics, multi-specifics, novel formats, and end-to-end insights in upstream & downstreamprocessing.

Follow the full journey of ADC innovation - smarter design, translational success,
and strategies to boost efficacy while minimising toxicity. Learn from case studies and
preclinical data powering safer, next-generation conjugates.

NextGen Biomed - What to Expect Presenting 2
NextGen Biomed - What to Expect Networking 4
1000

leading pharma, biotech, regulatory & academic delegates

700
pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments
NGB + LSX Combined Logo-1

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things NextGen Biomed, direct to your inbox.

NGB Newsletter Icon-1

Proteins, Antibodies, ADCs Agenda at a Glance

PRE-EVENT FOCUS DAY - 24 MARCH

Track 1: Protein & Antibody Engineering  
Track 2: Protein & Antibody Design  
Track 3: Novel Computational Tools & Technologies

DAY ONE - 25 MARCH

Track 1: Antibody Discovery & Selection: Novel Tools & Technologies 
Track 2: ADC Design, Validation & Optimisation to Enhance Their Therapeutic Potential 
Track 3: Emerging Analytical Techniques, Developability & Quality Control Systems
Track 4: Bioprocessing: Upstream Development: Novel Strategies for Cell Line Development & Expression Optimisation  
Track 5: NextGen Multi-Specifics, Cell Engagers & Other New Modalities  

DAY TWO - 26 MARCH

Track 1: AI/ML-Guided Protein & Antibody Engineering
Track 2: ADC Pre-Clinical & Translational Development 
Track 3:  Analytical Development: Stability & In-Depth Characterisation Methods for Proteins & Antibodies 
Track 4: Downstream Development: Protein Purification & Recombinant Protein Production

NextGen Biomed Conference Brochure

Meet Our Expert Speakers

Proteins & Antibodies again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Caroline Jane Barelle
Chief Executive Officer,
Elasmogen Ltd
Chris Herring
VP Safety,
T-Therapeutics
Karen Silence
Vice President, Head of Preclinical Product Development ,
Argenx
Paul Kellam
Chief Scientific Officer,
RQ Bio
Show More Speakers
Hide Speakers
Agnieszka Lewandowska
Associate Director Analytical Development,
Immunocore
Alice Canova
Global Regulatory Affairs Manager,
Pfizer Ltd
Amberley Stephens
Associate Principal Scientist,
AstraZeneca
Andreas Hollenstein
Principal Scientist, Immunosafety,
Roche
Andreas Plückthun
Full Professor of Biochemistry,
Universität Zürich
Angus Sinclair
Chief Scientific Officer,
LabGenius Therapeutics
Ásta Rós Sigtryggsdóttir
Head of Downstream Process Development,
Alvotech
Barbara Ciani
Senior Lecturer,
University of Sheffield
Beth Wensley
Principal Scientist - Protein and Analytical Sciences,
LifeArc
Birgit Piater
Head of Laboratory, Antibody Drug Conjugates,
Merck US
Blake Mazzitelli
Senior Scientist II,
Maxion Therapeutics
Charlotte Deane
Professor,
University of Oxford
Christian Hunzinger
Head of CMC Development Proteins, ADCs & Chemical Entities - Global Technical Development,
BioNTech
Christopher Lloyd
Director,
AstraZeneca
Chuang Kee Ong
Director Data Product,
GSK
Daniëlle van Wijk
Principal Scientist,
Byondis bv
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Dennis Ungan
Principal Scientist,
Novartis
Dimitri Sideris
Senior Scientist,
AstraZeneca
Dominic Hildebrand
Head of Quality Control / Global Lead Bioassays & CGT Analytics,
Bayer
Enkelejda Miho
Professor,
University of Applied Sciences and Arts Northwestern Switzerland
Ernst Weber
Head of Molecular Design & Engineering & Bayer Science Fellow,
Bayer AG
Fabio Centola
CQA Manager,
Merck & Cie KmG
Federico Riccardi Sirtori
Director, Head of NBE-DMPK Innovative Bioanalytics,
Merck & Cie KmG
Hans Melo
Chief Executive Officer,
Menten AI
Jamie Webster
Protein Expression Specialist,
University of Birmingham
Jing Li
Founder & Chief Executive Officer,
VelaVigo
Joost Uitdehaag
Head of Biology,
Crossfire Oncology B.V.
Justyna Mysliwy
Executive Director, Research,
Iksuda Therapeutics
Karin Hrovatin
Bioinformatic Scientist,
Merck & Cie KmG
Kate Smith
Head of Protein,
GSK
Katy Lloyd
Principal Scientist,
Genmab
Lolke De Haan
Vice President of Toxicology,
ADC Therapeutics (UK) Ltd
Marc Vendrell Escobar
Professor of Translational Chemistry,
University of Edinburgh
Marjolein Van Egmond
Professor in Oncology and Inflammation,
Amsterdam UMC Genome Diagnostics
Mark Austin
Associate Director In vitro Display,
AstraZeneca
Matthew Burke
Senior Scientist,
UCB
Mattia Cocco
Associate Director,
AstraZeneca
Mohammad Arastoo
Research Fellow,
University of Aberdeen
Nathan Alves
Research Director,
Indiana University School of Medicine
Nicola Burgess-Brown
Professorial Research Fellow & Chief Operating Officer, Protein Sciences,
Structural Genomics Consortium
Paolo Marcatili
Head of Antibody Design,
Novo Nordisk
Saif Shubber
Associate Director,
Bicycle Therapeutics
Silvia Crescioli
Business Intelligence Creator,
The Antibody Society
Sridhar Neelamraju
Associate Principal Informatician,
AstraZeneca
Steffen Goletz
Professor,
Technical University Denmark
Stephanie Linker
Senior Computational Biochemist,
Merck & Cie KmG
Steven Rust
Senior Director Protein Engineering,
Gilead Sciences
Tomasz Witkos
Associate Director,
AstraZeneca
Trevor Wattam
Associate Director,
GSK
Victor Goldmacher
Chief Scientific Officer,
Immuviatx

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Register Now

Be part of the new wave of Biomed R&D innovation

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients